

Gilead Sciences' Commitment to Global Elimination of Hepatitis C Virus

Son A¹, Khoshabafard D¹, Cheinquer N¹, Sajed N¹, Haubrich R¹, Platis S¹, Mignano J¹, Skaria A¹, Becker M¹, Zuka K¹, Attridge A¹, Chiang B¹, Israelski D¹, Mir H¹, Ryu J¹, Vanstraelen K¹, Soyemi T¹, Mertens M¹, Kreter B¹ ¹Gilead Sciences, Inc.

WHO Global Hepatitis Report



People living with **HCV** infection globally¹



14M Infected people diagnosed (20%)¹



Diagnosed patients initiated treatment (36%)²

Independent >700 clinical and non-clinical stakeholders **Medical Education 46** countries Supports programs that aim Medical to improve HCV management, focusing on PWID, co-infection, Affairs corrections and primary care hep capacity building Investigator-sponsored and collaborative studies support HCV >150,000 HCPs SLTC Summit elimination initiatives educated worldwide on HCV screening and linkage to care Valencia, Spain A multidisciplinary, (Sep 2017–Sep 2019) 79 in the Community international, patientstudies centered forum for Health best practice sharing 28 World Hepatitis Aliance in HCV management / तताला ` Addressing the **Global HCV Epidemic** EGA-C Through multiple departments, Gilead >471,499 supports governments, organizations, patients HCPs and payers to accelerate progress toward the reached **Investigator Meeting** WHO's 2030 goal for HCV elimination globally **72** HCPs and experts shared best practices Gilead maintains a global strategy toward for elimination-focused HCV elimination through: research at nited State investigator Partnerships and ongoing commitments to meetings V+ educational programs, ISRs, grants and patient 2019 The **24** investigators Vetherlands 7 countries 2018 Spain 2019 Lower and Middle 16 investigators Technology transfer and 7 countrie **32** investigato **Income Countries** voluntary licensing to generic manufacturers in lower- and 12 countrie middle-income countries Clinical Research >**99%** cured **TRAP-HepC test and treat:** Iceland on track to eliminate HCV 95% cured treated >**90%** omplete reatmen >98% cured

FOCUS partners do not use FOCUS awards for activities beyond linkage to a first medical appointment.

the US Preventive Services in the US) is a public health initiative enabling partners to develop and share best practices in routine blood-borne virus (HIV, HCV, HBV) screening, diagnosis and linkage to care in accordance with screening, diagnosis and linkage to care in accordance with screening guidelines promulgated by the US Preventive Services Task Force and state and local public health departments. In Spain and Portugal, FOCUS is a public health initiative that enables partners to develop and share best practices in routine blood-borne virus (HIV, HCV, and HBV screening, diagnosis, and linkage to a first medical appointment

1. WHO. Global Hepatitis Report, 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed November 2019); 2. WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed November 2019); 2. WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed November 2019); 2. WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed November 2019); 2. WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed November 2019); 2. WHO. DAA: direct-acting antiviral; FOCUS: Frontline of Communities in the US; HCP: healthcare professional; ISR: investigator-sponsored research; LEGA-C: Local Elimination Programs Leading to Global Action in HCV; PWID: people who inject drugs; SLTC: Screening and Linkage To Care; WHO: World Health Organization.



Public Affairs

In 2017, Gilead donated to organizations to help lessen the impact of HCV by:

- Educating patients and HCPs
- Reducing healthcare disparities
- Supporting local initiatives for
- the betterment of communities
- Improving access to care

HEPCONNECT

supports expansion of HCV screening and linkage to care, harm reduction and community education, and activating healthcare infrastructure

Between 2006 and 2012, acute HCV infections rose

364% among people under 30 in Central Appalachia

Government **Affairs and Policy**



Supported the development of a hepatitis health policy model, which was published and rolled out in >40 countries




Sharing best practices

'Road to Elimination' report on best practices and barriers in the care cascade for 11 countries 'Let's End Hep C', dashboard: compares countries' actions towards WHO 2030 goal



Facilitating policy advocacy

Partnered with advocacy and professional organizations to advocate for HCV elimination in Europe







HEP DART 2019 | December 08-12, 2019 | Grand Hyatt Kauai, Hawaii

